Okay. I think we have time for one more.
Operator
One more question, Steve Scala, Cowen.
Steve Scala - Cowen
Thank you. I have three questions. First, for Dr. Mackey, does Pfizer have the Dimebon Connection Data now? Do you plan on filing the monotherapy data this year? And when will that data be presented? That is the first question.
Secondly, I would like to follow up on the 2012 revenue questions. In January 2009 when Pfizer gave the revenue guidance, it anticipated Animal Health Divestitures to my recollection, is that not correct? And despite that anticipation, it was not in the guidance, is that how we should be viewing that situation?
And then thirdly, is the statement additionally our 2012 targets assume a modest level of planned business development activity? Is that the first time that language has been stated? Thank you.
Frank A. D’Amelio
So see. Let me answer the third and second question and then Martin will answer the first. In terms of business development being assumed in the 2012 targets, is that a new entry, the answer to that is no. That is not a new entry. I have said that before. We have said that before.
In terms of the Animal Health Divestitures being adjusted to the 2012 targets, the short answer is, we included. Let me say it differently. We knew Animal Health was going to be divested and we had made some assumptions for that. When we gave the $70 billion target that was based on, among other things, the combined revenue of both companies for 2008, which included all of the Animal Health revenues.
So the $70 billion, although we knew we were going to be making Animal Health Divestitures, we did not adjust the $70 billion for Animal Health Divestitures. So the answer to that is, it is not a new, it is a new entry relative to what was included and assumed in the $70 billion.
Jeffrey B. Kindler
Martin?
Martin Mackay
Just very quickly, Steve, we will, the Connection results will be available in the first half of 2010 and we will publish in that timeframe.
Jeffrey B. Kindler
Okay. There is one more question in the queue, so we might as well allow that person who has been waiting patiently. Operator?
Operator
Thank you. Final question from David Maris, CLSA.
David Maris - Calyon Securities
|
